Analysis of the Results of Combined Treatment of Ovarian Cancer Patients

The purpose of the study was the comparative analysis of the results of combined treatment of patients with common ovarian cancer. In this article we present the results of clinical observation of 129 patients with ovarian cancer on the III-IV (T3a-sNhM0-1) stages of the disease. These patients were treated under supervision of "GIMR NAMS of Ukraine" from 2014 to 2017. To conduct the comparative analysis of different treatment regimens effectiveness, the patients were divided into three groups. Patients in the first group (7% of all patients) received I-II cycles of neoadjuvant chemotherapy with subsequent surgical treatment; the second group patients (58.9%) got III-IV cycles of neoadjuvant chemotherapy with subsequent operative training; and the third group patients (34.1%) underwent surgical treatment followed by adjuvant chemotherapy. Analysis of the ovarian cancer (OC) patients distribution, depending on the stage of the disease and the histological structure of the tumor, allowed to establish that in patients with stage III of OC, serous cystadenocarcinoma is more likely to be detected more frequently than other types of tumors (χ2=13.4; p <0.05). At stage IV of the disease, there were no significant differences in the incidence of serous cystadenocarcinoma and other types of tumors. It was found out that in the IV stage of the OC there were significantly more frequent low-differentiated adenocarcinoma (χ2=6.1; p <0.05), serous cystadenocarcinoma or low-differentiated adenocarcinoma (χ2=5.9; p <0.05) than other types of tumors comparing with the III stage. The operative treatment of OC patients was to carry out the most possible cytodecimal operation. The extirpation or superficial amputation of the uterus with appendages in combination with resection or extirpation of the large gland was performed in 101 (78,2 ± 3,6)% of patients. The analysis of the relapse period in OC patients, depending on the stage of the disease and the scheme of antitumor therapy, showed that the average non-recurring survival rate of patients in all studied groups was in the range of 24.4 to 30 months. During the first year OC relapses occurred in 49 patients (89% of the number all patients with relapse). Differences in the relapses occurrence frequency in the first year of observation and later dates are reliable according to the criterion χ2 (χ2=33.5; p <0.05). It was established that the disease relapse risk is 3.7 times higher in the 7-12 months after treatment than 1-6 months after treatment (OR=3.7; F=0.006436). The risk of its relapse in the first a year is 9.8 times higher than relapsing on a later date (OR=9.38; F=0.000000). The analysis of relapses nature showed that the most often progression of the tumor process in patients, regardless of antitumor therapy scheme, was noted in the pelvic area (loco-regional relapse) – 24 (38.7%) patients and its generalization in the abdominal cavity or distant metastases – 27 (43.0%) patients. There were 87.3% of all relapses detected in the group of patients over the age of 51.